Navigation Links
Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
Date:6/26/2009

SEATTLE, June 26 /PRNewswire/ -- The Fred Hutchinson Cancer Research Center board of trustees today announced that its president and director, Lee Hartwell, Ph.D., plans to retire in June 2010. Hartwell, a recipient of the 2001 Nobel Prize in physiology or medicine, has been president and director of the Hutchinson Center since 1997.

"It's time," Hartwell said. "I have been president and director of the Center for 12 years. It's time for new leadership." Hartwell, who will turn 70 in October, says he informed the board's executive committee more than a year ago of his desire to retire and to begin the transition to new leadership. The exact timing of his departure was worked out over the last few months. The full board, faculty and staff were notified during the past two days.

Today's announcement was made by Doug Walker, chair of the Center's board of trustees, who said the search for Hartwell's successor will begin immediately. "Lee's leadership over these last 12 years has been extraordinary," Walker said. "It's hard for us to picture Fred Hutchinson Cancer Research Center without Lee at the helm. We're fortunate that Lee will be around to ensure that the transition to new leadership will be an extremely smooth one."

Walker says a search committee has been selected and it, in turn, will select a consultant to assist with the search. Board member Steve Davis, a senior adviser at McKinsey & Company, will head the search committee, which will also include members of the board and scientific faculty.

"The first thing we need to do is make a thorough assessment of the position and discuss the qualifications for the next Center leader with the Center's scientific faculty as well as community leadership," Walker said. "We'll use this information to determine the qualities and qualifications of the person we hope to recruit. Walker says there is no specific time frame attached to the search. "It will conclude when we have the best candidate for the position," he said.

After Hartwell retires in 2010, he hardly will be idle. He will continue to be involved with the Center as director emeritus and also will continue his work in early cancer detection and science education. He will also continue his role as chairman of the executive committee of the Partnership for Personalized Medicine, an Arizona-based global effort to improve patient outcomes and reduce health care costs.

At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please visit fhcrc.org.

    CONTACT:
    Kristen Woodward
    206-667-5095
    kwoodwar@fhcrc.org


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
2. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
3. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
4. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
5. Graphene pioneers follow in Nobel footsteps
6. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
7. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
8. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
9. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
10. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
11. Laureate Announces Manufacturing Agreement with Tolerx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):